Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Selpercatinib |
Trade Name | Retevmo |
Synonyms | LOXO-292|LOXO292|LOXO 292 |
Drug Descriptions |
Retevmo (selpercatinib) is an inhibitor of RET that specifically targets RET mutations and fusions, and may block the growth of cells with increased Ret activity (PMID: 29860229). Retevmo (selpercatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring RET fusions, and in adult and pediatric patient of 12 years and older with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer refractory to radioactive iodine (FDA.org). |
DrugClasses | RET Inhibitor 45 |
CAS Registry Number | 2222755-14-6 |
NCIT ID | C134987 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Crizotinib + Selpercatinib | Crizotinib Selpercatinib | 0 | 0 |
Dexamethasone + Selpercatinib | Dexamethasone Selpercatinib | 0 | 0 |
Larotrectinib + Selpercatinib | Larotrectinib Selpercatinib | 0 | 0 |
Osimertinib + Selpercatinib | Osimertinib Selpercatinib | 0 | 1 |
Selpercatinib | Selpercatinib | 35 | 9 |